Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.79 - pappalysin-1

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Habitual
Maternal serum free ss-hCG and PAPP-A in patients with habitual abortion-influence on first-trimester screening for chromosomal abnormalities.
Abortion, Spontaneous
A correlation analysis between the expression of pregnancy-associated plasma protein A in basal decidual cells and recurrent spontaneous abortion.
Are pregnancy-associated plasma protein-A (PAPP-A) and CA 125 measurements after IVF-ET possible predictors of early pregnancy wastage?
Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study.
Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Diagnostic accuracy of maternal serum macrophage inhibitory cytokine-1 and pregnancy-associated plasma protein-A at 6-10 weeks of gestation to predict miscarriage.
Effect of smoking on pregnancy-associated plasma protein A, free beta-human chorionic gonadotropin, and nuchal translucency in the first trimester of pregnancy.
Effects of fetal gender and low first trimester aneuploidy screening markers on preterm birth.
Fetal loss after chorionic villus sampling in twin pregnancy.
First trimester combined screening test for aneuploidies in anti-Ro carriers pregnant women.
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome?
First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss.
First-trimester serum PAPP-A and f?-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Low levels of pregnancy-associated plasma protein-A in asymptomatic women destined for miscarriage.
Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes.
Low pregnancy-associated plasma protein-a at 10(+1) to 14(+6) weeks of gestation and a possible mechanism leading to miscarriage.
Maternal level of pregnancy-associated plasma protein A as a predictor of pregnancy failure in threatened abortion.
Measurements of placental, decidual, and fetal proteins before and after chorionic villus sampling.
Predictive value of pregnancy-associated plasma protein-A in relation to fetal loss: A systematic review and meta-analysis.
Pregnancy-associated plasma protein A, free human chorionic gonadotrophin and nuchal translucency as predictors of miscarriage.
Prenatal diagnosis of partial monosomy 2q (2q37.3?qter) and partial trisomy 10q (10q24.31?qter) of paternal origin associated with increased nuchal translucency and abnormal maternal serum screening results.
Procedure-Related Fetal Loss following Chorionic Villus Sampling after First-Trimester Aneuploidy Screening.
Progesterone dependence and extratrophoblastic origin of pregnancy-associated plasma protein-A (PAPP-A) in early pregnancy.
The risk of adverse pregnancy outcome among pregnancies with extremely low maternal PAPP-A.
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Ultrasound and circulating placental protein measurements in complications of early pregnancy.
Abortion, Threatened
Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
First trimester screening for trisomy 21; Do the parameters used detect more pathologies than just Down syndrome?
Maternal level of pregnancy-associated plasma protein A as a predictor of pregnancy failure in threatened abortion.
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Pregnancy-associated protein-A does not improve predictability of pregnancy success or failure over human chorionic gonadotropin levels in early normal and abnormal pregnancy.
Value of Schwangerschaftsprotein 1 (SP1) and pregnancy-associated plasma protein-A (PAPP-A) in the clinical management of threatened abortion.
Abruptio Placentae
Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption.
First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Obstetric Outcome in Pregnant Patients with Low Level of Pregnancy-Associated Plasma Protein A in First Trimester.
Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.
Acute Coronary Syndrome
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome.
Association of calcium channel blocker use and pregnancy-associated plasma protein-A among older adults with hypertension: results from the ilSIRENTE study.
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Changes of pregnancy-associated plasma protein-A in patients with acute coronary syndrome.
Cigarette Smoking Increases Pregnancy-associated Plasma Protein-A in Men.
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.
Comment on immunoassays developed for pregnancy-associated plasma protein-A (PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes.
Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients.
Development of a sensitive and specific immunological test for detecting pregnancy-associated plasma protein A in patients with acute coronary syndrome.
Effect of routine heparins treatment in acute coronary syndrome on serum pregnancy-associated plasma protein a concentration.
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Elevated Serum Free Pregnancy-Associated Plasma Protein-A Independently Predicts Mortality in Haemodialysis Patients but Is Not Associated with Recurrent Haemodialysis-Induced Ischaemic Myocardial Injury.
Evaluation of pregnancy-associated plasma protein A as a prognostic indicator in acute coronary syndrome patients.
Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.
Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring.
Free vs Total Pregnancy-Associated Plasma Protein A (PAPP-A) as a Predictor of 1-Year Outcome in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome.
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Growth differentiation factor 15, ischemia modified albumin and pregnancy-associated plasma protein A in patients with coronary artery disease.
High positive predictive value of PAPP-A for acute coronary syndrome diagnosis in heparin-naïve patients.
Immunoassays developed for pregnancy-associated plasma protein-A (PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes.
Immunofluorometric point-of-care assays for the detection of acute coronary syndrome-related noncomplexed pregnancy-associated plasma protein A.
Increased levels of pregnancy-associated plasma protein A are associated with mortality in hemodialysis patients: preliminary results.
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study.
Influence of concomitant heparin administration on pregnancy-associated plasma protein-A levels in acute coronary syndrome with ST segment elevation.
Interplay between PAPP-A, inflammation and adiposity in patients with angiographically proven acute coronary syndrome (ACS).
Intravenous Administration of Low Molecular Weight and Unfractionated Heparin Elicits a Rapid Increase in Serum Pregnancy-Associated Plasma Protein A.
Level of Pregnancy-associated Plasma Protein-A Correlates With Coronary Thin-cap Fibroatheroma Burden in Patients With Coronary Artery Disease: Novel Findings From 3-Vessel Virtual Histology Intravascular Ultrasound Assessment.
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction.
Long-term prognostic utility of PAPP-A and calprotectin in suspected acute coronary syndrome.
Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy.
Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.
Novel biomarkers for cardiovascular risk prediction.
Novel markers in the acute coronary syndrome: BNP, IL-6, PAPP-A.
Optimisation of sandwich ELISA based on monoclonal antibodies for the specific measurement of pregnancy-associated plasma protein (PAPP-A) in acute coronary syndrome.
PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.
PAPP-A in cardiac and non-cardiac conditions.
PAPP-A: a marker of plaque instability. Is it ready for prime time?
Positive correlation between pregnancy-associated plasma protein-A level and OX40 ligand expression in patients with acute coronary syndromes.
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Pregnancy associated plasma protein-A (PAPP-A) as an early marker for the diagnosis of acute coronary syndrome.
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department.
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.
Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease.
Pregnancy-associated plasma protein A and procalcitonin as markers of myocardial injury in patients with acute coronary syndrome.
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Pregnancy-associated plasma protein a as predictor of outcome in patients with suspected acute coronary syndromes.
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Pregnancy-associated plasma protein A during hemodialysis with polyamide and diacetate cellulosic membranes.
Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.
Pregnancy-associated plasma protein A in dialysis patients.
Pregnancy-associated plasma protein A in non-cardiac conditions.
Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways.
Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI).
Pregnancy-associated plasma protein predicts outcomes of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome.
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Pregnancy-associated plasma protein-A and acute coronary syndromes: cause or consequence?
Pregnancy-associated plasma protein-A and the vulnerable plaque.
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis.
Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.
Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-NF-?B axis.
Pregnancy-associated plasma protein-a, a marker for outcome in patients suspected for acute coronary syndrome.
Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events.
Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris.
Prognostic Value of Ultra-sensitive Pregnancy Associated Plasma Protein-A in Patients with Acute Coronary Syndorme.
Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.
Relationship between Pregnancy-associated Plasma Protein-A and tissue factor levels in the coronary circulation of patients with acute coronary syndrome.
Relative value of serum pregnancy-associated plasma protein A (PAPP-A) and GRACE score for a 1-year prognostication: A complement to calculation in patients with suspected acute coronary syndrome.
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration.
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.
Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome.
[Acute coronary syndrome and inflammation. Biomarkers for diagnostics and risk stratification]
[Changes of plasma CD40L and PAPP-A in patients with acute coronary syndrome after the PCI operation]
[Effect of angiotensin II on pregnancy-associated plasma protein A and insulin-like growth factor 1 gene expression in human umbilical artery smooth muscle cells]
[Effects of C-reactive protein and tumor necrosis factor-alpha on mRNA expression of pregnancy-associated plasma protein-A in monocytes]
[Expression of COX-2 and pregnancy associate plasma protein A in coronary arteries and their relationship with acute coronary syndrome: an autopsy study of 42 cases]
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
[Meta-analysis on the prognostic value of pregnancy-associated plasma protein-A in acute coronary syndrome].
Acute Kidney Injury
Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Adenocarcinoma
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Adenoma
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Adenomyosis
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis.
Alzheimer Disease
Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.
Anaphylaxis
Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis.
Anemia
Human chorionic gonadotropin and plasma protein-A in alpha0-thalassemia pregnancies.
Anemia, Sickle Cell
Does first-trimester serum pregnancy-associated plasma protein A differ in pregnant women with sickle cell disease?
Angina Pectoris
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
Angina, Stable
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Level of Pregnancy-associated Plasma Protein-A Correlates With Coronary Thin-cap Fibroatheroma Burden in Patients With Coronary Artery Disease: Novel Findings From 3-Vessel Virtual Histology Intravascular Ultrasound Assessment.
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Measurement and clinical significance of circulating PAPP-A in ACS patients.
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris.
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Angina, Unstable
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Biomarkers for early detection of risk in female patients with coronary artery disease: pilot study.
Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Pregnancy-associated plasma protein-A as a marker of culprit lesion instability in unstable angina patients: an intravascular ultrasound study.
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
[Evaluation on the relationship between pregnancy associated plasma protein-a and intravascular ultrasound detected culprit coronary plaque morphology in patients with unstable angina].
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
[Placenta associated plasma protein-A (PAPP-A): clinical value in cardiovascular medicine]
Aortic Valve Stenosis
The relationship between serum pregnancy-associated plasma protein-A level in patients with aortic valve stenosis: a case-control study.
Asthma
Does pregnancy-associated plasma protein A have a role in allergic rhinitis?
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab.
Pregnancy-associated plasma protein-A and asthma.
Atherosclerosis
A coronary proatherosclerotic marker: Pregnancy-associated plasma protein A and its association with coronary calcium score and carotid intima-media thickness.
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?
Effects of mutated pregnancy-associated plasma protein-a on atherosclerotic lesion development in mice.
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Elevated serum levels of pregnancy-associated plasma protein-A in type 2 diabetics compared to healthy controls: associations with subclinical atherosclerosis parameters.
Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.
Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.
Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet.
Hsa-circ_0010283 Regulates Oxidized Low-Density Lipoprotein-Induced Proliferation and Migration of Vascular Smooth Muscle Cells by Targeting the miR-133a-3p/Pregnancy-Associated Plasma Protein A Axis.
Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study.
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
LncRNA XIST regulates atherosclerosis progression in ox-LDL-induced HUVECs.
MiR-182-5p Inhibits the Proliferation of Vascular Smooth Muscle Cells Induced by ox-LDL Through Targeting PAPPA.
Motor and memory testing of long-lived pregnancy-associated plasma protein--a knock-out mice.
Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
PAPP-A and the IGF system in Atherosclerosis - What's Up, What's Down?
PAPP-A in cardiac and non-cardiac conditions.
PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXR? through the IGF-I-mediated signaling pathway.
Pregnancy associated plasma protein-A (PAPP-A) as an early marker for the diagnosis of acute coronary syndrome.
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Pregnancy-associated plasma protein A (PAPP-A) in obese children: relation to markers and risk factors of atherosclerosis, and members of the IGF system.
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Pregnancy-Associated Plasma Protein A Induces Inflammatory Cytokine Expression by Activating IGF-I/PI3K/Akt Pathways.
Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease.
Pregnancy-Associated Plasma Protein-A Accelerates Atherosclerosis by Regulating Reverse Cholesterol Transport and Inflammation.
Pregnancy-associated plasma protein-A as a marker for long-term mortality in patients with peripheral atherosclerosis: inconclusive findings from the Linz Peripheral Arterial Disease (LIPAD) study.
Pregnancy-associated plasma protein-A in atherosclerosis: Molecular marker, mechanistic insight, and therapeutic target.
Pregnancy-associated plasma protein-a is associated with subclinical atherosclerosis in men with HIV infection.
Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation.
Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-NF-?B axis.
Pregnancy-associated plasma protein-A: an emerging cardiac biomarker.
Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk.
Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.
Surface association of pregnancy-associated plasma protein-A accounts for its colocalization with activated macrophages.
Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice.
Transgenic overexpression of pregnancy-associated plasma protein-A in murine arterial smooth muscle accelerates atherosclerotic lesion development.
[Association between IGF system and PAPP-A in coronary atherosclerosis].
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
[The carotid drainage system--a "window" into the atherosclerosis process in diabetics?]
Blood Group Incompatibility
Non-invasive fetal RHD genotyping in the first trimester of pregnancy.
Bone Diseases, Metabolic
Impact of pregnancy-associated plasma protein-a deletion on the adult murine skeleton.
The metalloproteinase Papp-aa controls epithelial cell quiescence-proliferation transition.
Breast Neoplasms
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes.
Collagen and PAPP-A in the Etiology of Postpartum Breast Cancer.
Expression of haptoglobin-related protein and its potential role as a tumor antigen.
Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.
Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer.
Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Pregnancy-associated plasma protein-A expression in human breast cancer.
Pregnancy-Associated Plasma Protein-A, Alpha-2-Macroglobulin, Pregnancy Zone Protein and Their Complexes with IgG in Sera of Healthy Non-Pregnant and Pregnant Woman, and Patients with Breast Cancer.
Prenatal Biochemical Screening and a Woman's Long-Term Risk of Cancer: A Population-Based Cohort Study.
Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study.
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.
The Non-coding Mammary Carcinoma Susceptibility Locus, Mcs5c, Regulates Pappa Expression via Age-Specific Chromatin Folding and Allele-Dependent DNA Methylation.
Breech Presentation
First trimester PAPP-A MoM values predictive for breech presentation at term of pregnancy.
Carcinogenesis
Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer.
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Carcinoma
Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo.
PAPP-A functions as a tumor suppressor and is downregulated in renal cell carcinoma.
PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma.
Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
The Non-coding Mammary Carcinoma Susceptibility Locus, Mcs5c, Regulates Pappa Expression via Age-Specific Chromatin Folding and Allele-Dependent DNA Methylation.
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Carcinoma, Hepatocellular
Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NF?B Signaling in Hepatocellular Carcinoma.
Carcinoma, Ovarian Epithelial
[Expression and activity of proteases in metastasis of ovarian cancer].
Carcinoma, Renal Cell
PAPP-A functions as a tumor suppressor and is downregulated in renal cell carcinoma.
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Cardiomyopathies
Comparative gene expression and phenotype analyses of skeletal muscle from aged wild-type and PAPP-A-deficient mice.
Cardiovascular Diseases
A combination of plaque components analyzed by integrated backscatter intravascular ultrasound (IB-IVUS) and serum pregnancy-associated plasma protein A (PAPP-A) levels predict the no-reflow phenomenon during percutaneous coronary intervention (PCI).
Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease.
Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease.
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Giant magnetoresistive-based biosensing probe station system for multiplex protein assays.
IGFBP-4 and PAPP-A in normal physiology and disease.
Inducible reduction in pregnancy-associated plasma protein-a gene expression inhibits established atherosclerotic plaque progression in mice.
Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?
Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.
Local IGF Bioactivity Associates with High PAPP-A Activity in the Pericardial Cavity of Cardiovascular Disease Patients.
Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) - intra- and inter-individual variability in chronic hemodialysis patients.
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay.
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease.
Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches.
Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis.
Pregnancy-associated plasma protein-A predicts survival in end-stage renal disease-confounding and modifying effects of cardiovascular disease, body composition and inflammation.
Pregnancy-associated plasma protein-A promotes TF procoagulant activity in human endothelial cells by Akt-NF-?B axis.
Targeted Inhibition of Pregnancy-Associated Plasma Protein-A Activity Reduces Atherosclerotic Plaque Burden in Mice.
[Inflammation, atherosclerosis and cardiovascular disease risk: PAPP-A, Lp-PLA2 and cystatin C. New insights or redundant information?]
Carotid Artery Diseases
Association of E-Selectin Gene Polymorphism and Serum PAPP-A with Carotid Atherosclerosis in End-Stage Renal Disease.
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Pregnancy-associated plasma protein-a is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques: a link between inflammation and cerebrovascular events.
Cerebrovascular Disorders
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Profile of serum pregnancy-associated plasma protein a after sustained subcutaneous low molecular weight heparin administration in patients with cerebrovascular diseases.
Cholestasis
Pregnancy-associated plasma protein a levels are decreased in obstetric cholestasis.
Cholestasis, Intrahepatic
First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy.
Chromosome Disorders
Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A.
Chronic Kidney Disease-Mineral and Bone Disorder
Pregnancy-associated plasma protein A in dialysis patients.
Confusion
Prognostic value of serum pregnancy-associated plasma protein A level at the initial ED presentation in elderly patients with CAP.
Congenital Abnormalities
Assessment of ?-human-derived chorionic gonadotrophic hormone (?hCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study.
The utility of pregnancy associated plasma protein-A MoM values in prediction of term respiratory distress syndrome.
Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes.
Whole-exome sequencing for diagnosis of Peters-plus syndrome after prenatal diagnosis of recurrent low PAPP-A and multiple fetal anomalies in two consecutive pregnancies.
Coronary Artery Disease
A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity.
Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease.
Growth differentiation factor 15, ischemia modified albumin and pregnancy-associated plasma protein A in patients with coronary artery disease.
Level of Pregnancy-associated Plasma Protein-A Correlates With Coronary Thin-cap Fibroatheroma Burden in Patients With Coronary Artery Disease: Novel Findings From 3-Vessel Virtual Histology Intravascular Ultrasound Assessment.
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Measurement and clinical significance of circulating PAPP-A in ACS patients.
MiR-182-5p Inhibits the Proliferation of Vascular Smooth Muscle Cells Induced by ox-LDL Through Targeting PAPPA.
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Pregnancy associated plasma protein-A and coronary atherosclerosis: marker, friend, or foe?
Pregnancy associated plasma protein-A and risk stratification of patients presenting with chest pain in the emergency department.
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease.
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease.
Pregnancy-associated plasma protein-A in atherosclerosis: Molecular marker, mechanistic insight, and therapeutic target.
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Pregnancy-associated plasma protein-A is an independent short-time predictor of mortality in patients on maintenance haemodialysis.
Pregnancy-Associated Plasma Protein-A Levels in Individuals with and without Coronary Artery Disease.
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina.
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.
The utility of pregnancy-associated plasma protein A for determination of prognosis in a cohort of patients with coronary artery disease.
Coronary Disease
Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease.
Positive correlation between pregnancy-associated plasma protein-A level and OX40 ligand expression in patients with acute coronary syndromes.
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up-A CLARICOR Trial Sub-Study.
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease.
Pregnancy-associated plasma protein A in non-cardiac conditions.
Pregnancy-associated plasma protein A predicts adverse vascular events in patients with coronary heart disease: a systematic review and meta-analysis.
Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk.
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
THE ROLE OF LIPOPROTEIN (A) AND PREGNANCY ASSOCIATED PLASMA PROTEIN A IN DIAGNOSTICS CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
[Laboratory diagnosis of atherosclerotic plaque damage in patients with coronary heart disease: PAPP-A (a review of literature)].
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Coronary Stenosis
Positive correlation between pregnancy-associated plasma protein-A level and OX40 ligand expression in patients with acute coronary syndromes.
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Pregnancy-associated plasma protein predicts outcomes of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome.
Prognostic value of circulating pregnancy-associated plasma protein-A (PAPP-A) and proform of eosinophil major basic protein (pro-MBP) levels in patients with chronic stable angina pectoris.
Craniosynostoses
Prenatal diagnosis and molecular cytogenetic characterization of de novo pure partial trisomy 6p associated with microcephaly, craniosynostosis and abnormal maternal serum biochemistry.
Cysts
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle.
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
De Lange Syndrome
Assignment of the human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in situ hybridization to mitotic and meiotic chromosomes.
Low first-trimester pregnancy-associated plasma protein-A and Cornelia de Lange syndrome.
Pregnancy-associated plasma protein A: a possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndrome.
Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnancies.
Death, Sudden, Cardiac
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Decompression Sickness
Papp-a2 modulates development of cranial cartilage and angiogenesis in zebrafish embryos.
Dementia
Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.
Developmental Dysplasia of the Hip
Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip: a case-control study.
Expression of PAPP-A2 and IGF Pathway-Related Proteins in the Hip Joint of Normal Rat and Those with Developmental Dysplasia of the Hip.
Diabetes Mellitus
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Association between pregnancy-associated plasma protein-A levels in the first trimester and gestational diabetes mellitus in Chinese women.
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
First Trimester Aneuploidy Screening Markers in Women with Pre-Gestational Diabetes Mellitus.
First trimester maternal serum free ?-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
First trimester PAPP-A serum levels and long-term metabolic outcome of mothers and their offspring.
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers.
Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies.
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Pregnancy-associated plasma protein A and mortality in haemodialysis.
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Temporal Effect of Afro-Caribbean Race on Serum Pregnancy-Associated Plasma Protein-A at 9-13 Weeks' Gestation in Screening for Aneuploidies.
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Diabetes Mellitus, Type 1
A re-evaluation of the influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Impact of type 1 diabetes and glycemic control on fetal aneuploidy biochemical markers.
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Diabetes Mellitus, Type 2
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A.
PAPP-A activity is increased in cerebrospinal fluid from patients with diabetic polyneuropathy and correlates with peripheral nerve impairment.
Pregnancy-associated plasma protein-a levels are related to glycemic control but not to lipid profile or hemostatic parameters in type 2 diabetes.
Diabetes, Gestational
Association between pregnancy-associated plasma protein-A and gestational diabetes requiring insulin treatment at 11-14 weeks of gestation.
Association between pregnancy-associated plasma protein-A levels in the first trimester and gestational diabetes mellitus in Chinese women.
Can first-trimester screening program detect women at high risk for gestational diabetes mellitus?
Early Pregnancy-Associated Plasma Protein A Concentrations are Associated with Third Trimester Insulin Sensitivity.
Evaluation of maternal and perinatal outcomes among overweight women who experienced stillbirth.
First Trimester Combined Test (FTCT) as a Predictor of Gestational Diabetes Mellitus.
First trimester maternal serum free ?-human chorionic gonadotropin and pregnancy-associated plasma protein A in pregnancies complicated by diabetes mellitus.
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes.
First trimesters Pregnancy-Associated Plasma Protein-A levels value to Predict Gestational diabetes Mellitus: A systematic review and meta-analysis of the literature.
First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus.
Gestational diabetes mellitus and first trimester pregnancy-associated plasma protein A: A case-control study in a Chinese population.
Gestational diabetes mellitus: including serum pregnancy-associated plasma protein-A testing in the clinical management of primiparous women? A case-control study.
Maternal Diabetes, Large-for-Gestational-Age Births, and First Trimester Pregnancy-Associated Plasma Protein-A.
Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study.
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
PAPP-A concentrations change in patients with gestational diabetes.
Potential role of biochemical placentation markers - pregnancy associated plasma protein-A and human chorionic gonadotropin for early gestational diabetes screening - a pilot study.
Prediction of Gestational Diabetes by Measuring the Levels of Pregnancy Associated Plasma Protein-A (PAPP-A) During Gestation Weeks 11-14.
Pregnancy-associated plasma protein-A2 levels are increased in early-pregnancy gestational diabetes: a novel biomarker for early risk estimation.
Studies on the concentration of pregnancy-associated plasma protein-A during normal and complicated pregnancy.
Study on the correlation and predictive value of serum pregnancy-associated plasma protein A, triglyceride and serum 25-hydroxyvitamin D levels with gestational diabetes mellitus.
Temporal Variation in Soluble Human Leukocyte Antigen-G (sHLA-G) and Pregnancy-Associated Plasma Protein A (PAPP-A) in Pregnancies Complicated by Gestational Diabetes Mellitus and in Controls.
The association between gestational diabetes mellitus and first trimester aneuploidy screening markers.
The Immunosignature of Mother/Fetus Couples in Gestational Diabetes Mellitus: Role of HLA-G 14?bp ins/del and PAPP-A A/C Polymorphisms in the Uterine Inflammatory Milieu.
Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study.
Diabetic Nephropathies
Mice deficient in PAPP-A show resistance to the development of diabetic nephropathy.
Motor and memory testing of long-lived pregnancy-associated plasma protein--a knock-out mice.
PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow--up study.
Diabetic Neuropathies
PAPP-A activity is increased in cerebrospinal fluid from patients with diabetic polyneuropathy and correlates with peripheral nerve impairment.
Down Syndrome
A First-Trimester Biomarker Panel for Predicting the Development of Gestational Diabetes.
A re-assessment of biochemical marker distributions in T21 affected and unaffected twin pregnancies in the first trimester.
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies.
ACOG Committee Opinion #296: first-trimester screening for fetal aneuploidy.
Additional performance of nasal bone in first trimester screening.
Additive effect of factors related to assisted conception on the reduction of maternal serum PAPP-A concentrations and the increased false-positive rates in first-trimester Down syndrome screening.
Advances in prenatal screening for Down syndrome: II first trimester testing, integrated testing, and future directions.
Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A.
Aneuploidy screening in the first trimester.
Appropriate biochemical parameters in first-trimester screening for Down syndrome.
Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Assessment of the value of reporting partial screening results in prenatal screening for Down syndrome.
Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Autocorrelation and cross-correlation between hCG? and PAPP-A in repeated sampling during first trimester of pregnancy.
Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited.
Biochemical markers of trisomy 21 and the pathophysiology of Down's syndrome pregnancies.
Biological variation of free ? chorionic gonadotropin and pregnancy-associated plasma protein A in first trimester pregnancies.
Combined first-trimester Down syndrome screening in HIV-infected women.
Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome.
Comparing first trimester screening performance: routine care gynaecologists' practices vs. prenatal centre.
Comparison of combined, biochemical and nuchal translucency screening for Down's syndrome in first trimester in Northern Finland.
Comparison of First Trimester Screening for Down's Syndrome Using Free Beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein-A Levels between Spontaneous and IVF Pregnancies at 12 Weeks of Gestation.
Comparison of Nicolaides' risk evaluation for Down's syndrome with a novel software: an analysis of 1,463 cases.
Comparison of serum markers in first-trimester down syndrome screening.
Comparison of the new PRC software with the established algorithm of the FMF UK for the detection of trisomy 21 and 18/13.
Comparison of Three First Trimester Screening Algorithms for Trisomy 21 with and without Adjustment for Maternal Characteristics.
Comparison of two immunoassay systems for hCG? and PAPP-A in prenatal screening for trisomy 21, 18, and 13 in the first trimester.
Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Diagnosis of fetal acrania during the first trimester nuchal translucency screening for Down syndrome.
Diagnostic value of ultrasonographic combining biochemical markers for Down syndrome screening in first trimester: a meta-analysis.
Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13+6 weeks of gestation.
Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome.
Early first-trimester free beta-hCG and PAPP-A serum distributions in monochorionic and dichorionic twins.
Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency.
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
Effect of deviation of nuchal translucency measurements on the performance of screening for trisomy 21.
Effect of ethnicity on first trimester biomarkers for combined trisomy 21 screening: results from a multicenter study in six Asian countries.
Effect of fetal gender on first trimester markers and on Down syndrome screening.
Erroneous production of PAPP-A kits: the impact of a downward shift in PAPP-A concentration on the test performance of first-trimester combined screening for Down syndrome.
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures.
Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland.
Evaluation of indications for amniocentesis in cases of normal fetal ultrasound results.
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access(®) platform: suitability for use in first trimester Down's syndrome screening.
Fine-tuning ofroutine combined first- trimester screening: The ratio of serum-free- beta-human chorionic gonadotropin (f?-hCG) to pregnancy-associated plasma protein-A (PAPP-A) could improve performance of Down syndrome screening program, a retrospective cohort study in Iran.
First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproduction.
First trimester combined screening for Trisomy 21 in Hong Kong: outcome of the first 10,000 cases.
First trimester combined screening for trisomy 21 with different combinations of placental growth factor, free ?-hCG and PAPP-A.
First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay.
First trimester Down syndrome screening: Distribution of markers and comparison of assays for quantification of pregnancy-associated plasma protein-A.
First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
First trimester increased nuchal translucency associated with fetal achondroplasia.
First trimester maternal serum free human chorionic gonadotropin as a predictor of adverse pregnancy outcome.
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.
First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free ?-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.
First trimester PAPP-A in the detection of non-Down syndrome aneuploidy.
First trimester predictors of adverse pregnancy outcomes.
First trimester prenatal diagnosis of trisomy 21 in discordant twins using fetal nuchal translucency thickness and maternal serum free beta-hCG and PAPP-A.
First trimester screening for aneuploidy: serum biochemical markers.
First trimester screening for Down syndrome using free beta hCG, total hCG and PAPP-A: an exploratory study.
First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-? human chorionic gonadotrophin, placental growth factor, and ?-fetoprotein.
First trimester screening for Down's syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10-14 weeks of gestation.
First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness.
First trimester serum tests for Down's syndrome screening.
First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
First trimester uterine artery pulsatility index levels in euploid and aneuploid pregnancies.
First- and second-trimester evaluation of risk for Down syndrome.
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
First-trimester biochemical screening for Down syndrome with the use of PAPP-A, AFP, and beta-hCG.
First-trimester biochemical screening for Down syndrome.
First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
First-trimester combined screening for trisomy 21 in a predominantly Chinese population.
First-trimester combined screening is effective for the detection of unbalanced chromosomal translocations at 11 to 12 weeks of gestation.
First-trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population.
First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
First-trimester Down syndrome screening: component analytes and timing for optimal performance.
First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
First-trimester maternal dried blood Down syndrome screening marker levels in early pregnancy loss.
First-trimester maternal serum level of pregnancy-associated plasma protein-A is an independent predictor of fetal maxillary bone length.
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
First-trimester screening for aneuploidy: research or standard of care?
First-trimester screening for chromosomal abnormalities.
First-trimester screening for Down syndrome in singleton pregnancies achieved by intrauterine insemination.
First-trimester screening for Down syndrome using nuchal translucency measurement with free beta-hCG and PAPP-A between 10 and 13 weeks of pregnancy--the combined test.
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
First-trimester screening for trisomies in pregnancies with vanishing twin.
First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction.
First-trimester screening for trisomy 21 using alpha-fetoprotein.
First-Trimester Screening for Trisomy 21 with Adjustment for Biochemical Results of Previous Pregnancies.
First-trimester screening with nasal bone in twins.
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Frequency and clinical consequences of extremely high maternal serum PAPP-A levels.
Frontomaxillary facial angle at 11 + 0 to 13 + 6 weeks in Chinese population.
Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies.
Higher median levels of free beta-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population.
Human chorionic gonadotropin and plasma protein-A in alpha0-thalassemia pregnancies.
Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell-free fetal DNA.
Immunoassay-Amplified Responses Using a Functionalized MoS2-Based SPR Biosensor to Detect PAPP-A2 in Maternal Serum Samples to Screen for Fetal Down's Syndrome.
Impact of replacing or adding placental growth factor on Down syndrome screening: A prospective cohort study.
Impact of the Maternal Age-Related Risk in First-Trimester Combined Screening for Trisomy 21.
Implementation of One-Stop-Clinic for Risk Assessment of chromosomal abnormalities in the first trimester, evaluating the effectiveness and making it part of our daily practice.
Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women.
Influence of first trimester biochemistry methodology on detection rate in screening for trisomy 21.
Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters.
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Interstitial pregnancy undetected during earlier first-trimester screening for fetal aneuploidy at 13 weeks' gestation.
Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
Longer time-to-pregnancy in spontaneously conceived pregnancies is associated with lower PAPP-A and free ?-hCG in first trimester screening for Down syndrome.
Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association with abnormal fetal karyotype.
Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks.
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.
Maternal serum free ss-hCG and PAPP-A in patients with habitual abortion-influence on first-trimester screening for chromosomal abnormalities.
Maternal serum human chorionic gonadotrophin and pregnancy-associated plasma protein A, markers for fetal Down syndrome at 8-14 weeks.
Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies.
Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester.
Maternal serum levels of placental proteins after in vitro fertilisation and their implications for prenatal screening.
Maternal serum levels of total activin-A in first-trimester trisomy 21 pregnancies.
Maternal serum placental growth factor and ?-fetoprotein testing in first trimester screening for Down syndrome.
Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies.
Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
Maternal serum pregnancy-associated plasma protein-A and free beta-human chorionic gonadotrophin in pregnancies conceived with fresh and frozen-thawed embryos from in vitro fertilization and intracytoplasmic sperm injection.
Maternal serum screening for fetal genetic disorders.
Maternal serum screening marker levels in women with a previous aneuploidy pregnancy.
Maternal serum soluble HLA-G in complicated pregnancies.
Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy.
Median levels of serum biomarkers of fetal Down syndrome detected during the first trimester among pregnant Thai women.
Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
Meta-analysis of first trimester Down syndrome screening studies: free beta-human chorionic gonadotropin significantly outperforms intact human chorionic gonadotropin in a multimarker protocol.
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nasal bone in screening for T21 at 11-13 + 6 weeks of gestation - a multicenter study.
Normal range of intracranial translucency (IT) assessed by three-dimensional ultrasound at 11?+?0 to 13?+?6 weeks in a Chinese population.
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Observational study comparing the performance of first-trimester screening protocols for detecting trisomy 21 in a North Indian population.
One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies.
OP19.01: PAPP-A and beta-hCG as markers of low birth weight and preterm delivery in a consecutive cohort of 1867 pregnancies undergoing combined first trimester screening for Down syndrome.
Optimisation of sandwich ELISA based on monoclonal antibodies for the specific measurement of pregnancy-associated plasma protein (PAPP-A) in acute coronary syndrome.
Pattern of secretion of pregnancy-associated plasma protein-A (PAPP-A) during pregnancies complicated by fetal aneuploidy, in vivo and in vitro.
Performance of free beta-human chorionic gonadotrophin (free beta-hCG) and pregnancy associated plasma protein-A (PAPP-A) analysis between Delfia Xpress and AutoDelfia systems in The Netherlands.
PLAC4 and beta-HCG mRNA levels are not altered in the maternal circulation of pregnancies with trisomy 21.
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: use in first-trimester screening for Down syndrome.
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A.
Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome.
Pregnancy associated plasma protein-A2: a novel biomarker for Down syndrome.
Pregnancy outcome in the setting of extremely low first trimester PAPP-A levels.
Pregnancy-associated plasma protein A (PAPP-A), a first-trimester screening test for Down syndrome and other chromosomal anomalies.
Pregnancy-associated plasma protein A (PAPP-A): measurement by highly sensitive and specific enzyme immunoassay, importance of first-trimester serum determinations, and stability studies.
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Pregnancy-associated plasma protein-E (PAPP-E).
Prenatal diagnosis of partial monosomy 2q (2q37.3?qter) and partial trisomy 10q (10q24.31?qter) of paternal origin associated with increased nuchal translucency and abnormal maternal serum screening results.
Prenatal diagnostic testing and atypical chromosome abnormalities following combined first-trimester screening: implications for contingent models of non-invasive prenatal testing.
Prenatal screening for Down syndrome in twin pregnancies: Estimates of screening performance based on 61 affected and 7302 unaffected twin pregnancies.
Prenatal screening in the first trimester of pregnancy.
Prenatal Screening Markers for Down Syndrome: Sensitivity, Specificity, Positive and Negative Expected Value Method.
Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.
Production and characterization of monoclonal antibodies against pregnancy-associated plasma protein A.
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free ?-hCG.
Prospective validation of first-trimester combined screening for trisomy 21.
Quantification of proteolytically active pregnancy-associated plasma protein-A with an assay based on quenched fluorescence.
Re: First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free ?-human chorionic gonadotropin and pregnancy-associated plasma protein-A. K. O. Kagan, M. Hoopmann, H. Abele, R. Alkier and K. Lüthgens. Ultrasound Obstet Gynecol 2012; 40: 530-535.
Reference centile chart for fetal nuchal translucency, maternal serum PAPP-A and free beta hCG.
Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study.
Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population.
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
Screening for aneuploidy in first and second trimesters: is there an optimal paradigm?
Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.
Screening for Down's syndrome in early and late first and second trimester using six maternal serum markers.
Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters.
Screening for fetal aneuploidies at 11 to 13 weeks.
Screening for fetal trisomy 21 in gestational weeks 6 and 7.
Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Screening for trisomy 21 in twin pregnancies in the first trimester using free beta-hCG and PAPP-A, combined with fetal nuchal translucency thickness.
Screening for trisomy 21 in twin pregnancies in the first trimester: does chorionicity impact on maternal serum free beta-hCG or PAPP-A levels?
Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18.
Second trimester two-step trisomy 18 screening using maternal serum markers.
Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Second-trimester maternal pregnancy-associated plasma protein a and inhibin a levels in fetal trisomies.
Sequential pathways of testing after first-trimester screening for trisomy 21.
Serum leptin in first-trimester Down syndrome pregnancies.
Serum PAPP-A and free beta-hCG are first-trimester screening markers for Down syndrome.
Serum PAPP-A levels are depressed in women with fetal Down syndrome in early pregnancy.
Serum PAPP-A measurements in first-trimester screening for Down syndrome.
SURUSS in perspective.
Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy.
The clinical usefulness of biochemical (free ?-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
The first-trimester screen in clinical practice.
The impact of bias in serum-free ?-hCG and PAPP-A MoM levels on first trimester screening for trisomy 21.
The impact of bias in the crown rump length measurement on first trimester screening for trisomy 21.
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies.
The impact of temporal variability of biochemical markers PAPP-A and free beta-hCG on the specificity of the first-trimester Down syndrome screening: a Croatian retrospective study.
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
The influence of smoking on maternal serum PAPP-A and free beta hCG levels in the first trimester of pregnancy.
The NTplus method of screening for Down syndrome: achieving the 2010 targets?
The relationship between environmental exposures and hormonal abnormalities in pregnant women: An epidemiological study in Yazd, Iran.
The use of nuchal translucency in contemporary obstetric practice.
The utility of circulating LHCGR as a predictor of Down's syndrome in early pregnancy.
Time-resolved immunofluorometric assay of pregnancy-associated plasma protein A in maternal serum screening for Down's syndrome in first trimester of pregnancy.
Total pregnancy-associated plasma protein A--a first trimester maternal serum marker for Down's syndrome: clinical and technical assessment of a poly-monoclonal enzyme immunoassay.
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Ultrasound and fetal diagnosis.
Undetectable pregnancy-associated plasma protein-A in antenatal serum Down's syndrome screening: a case of assay interference.
Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
Urinary hyperglycosylated hCG in first trimester screening for chromosomal abnormalities.
Will PAPP-A be a biochemical marker for screening of Down's syndrome in the first trimester?
[Clinical study of assessment of trisomy 21--precise risk evaluation in the first trimester of pregnancy]
[Cross-Validation of the First Trimester Screening Algorithm of the FMF London on 38 700 Pregnancies in Germany].
[Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research]
[Fetal erythroblasts from maternal blood for prenatal genetic diagnosis]
[Low PAPP-A levels between 11 and 13(+6) weeks of gestation and the risk of preeclampsia].
[Measurement of pregnancy-associated plasma protein A in maternal peripheral blood and Down syndrome]
[PAPP-A in the first trimester of pregnancy]
[Prenatal diagnosis of Down syndrome: study of correlations between two types of blood collection tubes].
[Prenatal risk calculation: comparison between Fast Screen pre I plus software and ViewPoint software. Evaluation of the risk calculation algorithms].
[Screening by maternal serum markers for Down's syndrome]
Dyslipidemias
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Eclampsia
Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction.
Endometrial Neoplasms
Immunohistochemical localization of placental proteins and tumor-associated antigens in endometrial cancer and endometrial hyperplasia.
Endometriosis
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis.
Increased pregnancy-associated plasma protein-A (PAPP-A) concentrations in peritoneal fluid of women with endometriosis.
Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis.
PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis.
The endometrial response to chorionic gonadotropin is blunted in a baboon model of endometriosis.
Epilepsy
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Essential Hypertension
Associations of pregnancy-associated plasma protein-A level with essential hypertension and hypertensive disorders in pregnancy in Chinese population: a meta-analysis of 20 research studies involving 3332 individuals.
Fatty Liver
Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.
Fetal Death
Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome.
Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.
Both Low and High PAPP-A Concentrations in the First Trimester of Pregnancy Are Associated with Increased Risk of Delivery before 32 Weeks in Twin Gestation.
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Does Low PAPP-A Predict Adverse Placenta-Mediated Outcomes in a Low-Risk Nulliparous Population? the Great Obstetrical Syndromes (GOS) Study.
First-trimester screening for trisomies in pregnancies with vanishing twin.
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Obstetric Outcome in Pregnant Patients with Low Level of Pregnancy-Associated Plasma Protein A in First Trimester.
RU 486 mediated leukocytic inflammatory reaction at the utero-placental interface.
The role of trophoblast dysfunction in the aetiology of miscarriage.
Fetal Growth Retardation
ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts.
Are 1st-trimester ?-human chorionic gonadotrophin and pregnancy-associated plasma protein A levels predictive of intrapartum fetal compromise in a selected normal population?
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Association between fetal fraction on cell-free DNA testing and first trimester markers for pre-eclampsia.
Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome.
Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
Biochemical markers in screening for preeclampsia and intrauterine growth restriction.
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Distinction between fetal growth restriction and small for gestational age newborn weight enhances the prognostic value of low PAPP-A in the first trimester.
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
Efficiency of first-trimester growth restriction and low pregnancy-associated plasma protein-A in predicting small for gestational age at delivery.
Evaluation of biochemical markers combined with uterine artery Doppler parameters in fetuses with growth restriction: a case-control study.
Evaluation of maternal and perinatal outcomes among overweight women who experienced stillbirth.
First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction.
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction.
First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system.
First-trimester placental volume and vascularization measured by 3-dimensional power Doppler sonography in pregnancies with low serum pregnancy-associated plasma protein a levels.
First-trimester screening for fetal growth restriction using Doppler color flow analysis of the uterine artery and serum PAPP-A levels in unselected pregnancies.
First-trimester umbilical vein blood flow in pregnancies with low serum pregnancy-associated plasma protein-A levels: an early predictor of fetal growth restriction.
Identification of a prenatal profile of Cornelia de Lange syndrome (CdLS): A review of 53 CdLS pregnancies.
Is there a relationship between cord blood pregnancy-associated plasma protein-A and birth weight and length?
Low PAPP-A: the impact of ultrasound to evaluate fetal growth.
Maternal serum levels of free beta-hCG and PAPP-A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery.
Measurement of plasma placental proteins and estriol in the detection of intrauterine growth retardation.
New Predictive Model at 11+0 to 13+6 Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction.
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.
Predictive value of pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG on fetal growth restriction: results of a prospective study.
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Pregnancy-associated plasma protein A for prediction of fetal growth restriction.
Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction.
Rare autosomal trisomies: Important and not so rare.
Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency.
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.
Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies.
Second-trimester fetal growth as a predictor of poor obstetric and neonatal outcome in patients with low first-trimester serum pregnancy-associated plasma protein-A and a euploid fetus.
Significance of pregnancy-associated plasma protein A (PAPP-A) concentration determination in the assessment of final outcome of pregnancy.
Studies on the concentration of pregnancy-associated plasma protein-A during normal and complicated pregnancy.
The evaluating of pregnancy-associated plasma protein-A with the likelihood of small for gestational age.
The Impact of First-Trimester Serum Free beta-Human Chorionic Gonadotropin and Pregnancy-Associated Plasma Protein A on the Diagnosis of Fetal Growth Restriction and Small for Gestational Age Infant.
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
[Detection of pregnancy-specific beta 1-glycoproteins (SP1) and pregnancy-associated plasma protein A (PAPP-A) in maternal serum. Diagnostic significance in intrauterine fetal retardation]
Fetofetal Transfusion
A trend toward increased first trimester free beta-hCG and PAPP-A in monochorionic twins complicated by Twin-to-Twin Transfusion syndrome.
Galactosemias
Cryopreservation of ovarian tissue may be considered in young girls with galactosemia.
Gastroschisis
Frequency and clinical consequences of extremely high maternal serum PAPP-A levels.
Genetic Diseases, Inborn
Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse.
Glucose Intolerance
Incorporating first trimester analytes to predict delivery of a large for gestational infant in women with impaired glucose tolerance.
PAPP-A concentrations change in patients with gestational diabetes.
Granulosa Cell Tumor
Insulin-like growth factor, insulin-like growth factor-binding protein-4, and pregnancy-associated plasma protein-A gene expression in human granulosa cell tumors.
Headache Disorders
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Heart Defects, Congenital
First trimester combined screening biochemistry in detection of congenital heart defects.
Heart Diseases
Detection of multiple cardiac markers with an integrated acoustic platform for cardiovascular risk assessment.
Pregnancy-associated plasma protein A and mortality in haemodialysis.
Pregnancy-associated plasma protein A in non-cardiac conditions.
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Heart Failure
Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Serum pregnancy-associated plasma protein a in patients with heart failure.
Heart Septal Defects, Ventricular
First trimester combined screening biochemistry in detection of congenital heart defects.
HELLP Syndrome
PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome.
Hepatitis B
Effect of Maternal Hepatitis B Carrier Status on First-Trimester Markers of Down Syndrome.
Hirsutism
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
HIV Infections
Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
Pregnancy-associated plasma protein-a is associated with subclinical atherosclerosis in men with HIV infection.
Hydatidiform Mole
Placenta-associated plasma protein-A (PAPP-A, SP4) in trophoblastic tumours.
Pregnancy-associated protein-A does not improve predictability of pregnancy success or failure over human chorionic gonadotropin levels in early normal and abnormal pregnancy.
Progesterone dependence and extratrophoblastic origin of pregnancy-associated plasma protein-A (PAPP-A) in early pregnancy.
Prognostic significance of the new placental proteins in trophoblastic disease.
The contribution of maternal serum markers in the early prenatal diagnosis of molar pregnancies.
Hydatidiform Mole, Invasive
Placenta-associated plasma protein-A (PAPP-A, SP4) in trophoblastic tumours.
Hypercholesterolemia
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Hyperemesis Gravidarum
First trimester maternal serum PAPP-A and free ?-HCG levels in hyperemesis gravidarum.
Maternal serum pregnancy-associated plasma protein-A levels in hyperemesis gravidarum: a prospective case control study.
Hyperglycemia
PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
Hyperlipidemias
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Hypertension
Are first-trimester ultrasound features prior to 11?weeks' gestation and maternal factors able to predict maternal hypertensive disorders?
Association of calcium channel blocker use and pregnancy-associated plasma protein-A among older adults with hypertension: results from the ilSIRENTE study.
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Association of first-trimester low PAPP-A levels with preterm birth.
Associations of plasma PAPP-A2 and genetic variations with salt sensitivity, blood pressure changes and hypertension incidence in Chinese adults.
Cardiac Biomarkers and Cardiovascular Outcome in Children with Chronic Kidney Disease.
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Development and Validation of a Risk Factor Scoring System for First-Trimester Prediction of Preeclampsia.
Early prediction of hypertension during pregnancy in a low-resource setting.
Early Pregnancy Maternal Serum PAPP-A and Urinary Protein-Creatinine Ratio as Predictive Markers of Pregnancy Induced Hypertension.
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension.
First trimester PAPP-A2, PAPP-A and hCG? in small-for-gestational-age pregnancies.
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
First-trimester prediction of hypertensive disorders in pregnancy.
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
MoM cutoffs for variables, an important tool for multivariate analysis and accurate interpretation of preeclampsia risk in high-risk pregnancy at 11-13(+6) weeks gestation.
Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies.
Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free ?-hCG.
Predictive value of combined serum biomarkers for adverse pregnancy outcomes.
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris.
Role of maternal factors, PAPP-A, and Doppler in screening for early- and late-onset pregnancy hypertension in Asian population.
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Ultrasound placental image texture analysis using artificial intelligence to predict hypertension in pregnancy.
Hypertension, Pregnancy-Induced
A prospective study of screening for hypertensive disorders of pregnancy at 11-13 weeks in a Scandinavian population.
Association of pregnancy-associated plasma protein A and vascular endothelial growth factor with pregnancy-induced hypertension.
Biochemical Markers for Prediction of Hypertensive Disorders of Pregnancy.
Correlation between First-Trimester Maternal Serum Markers, Second-Trimester Uterine Artery Doppler Indices and Pregnancy Outcome.
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Early Pregnancy Maternal Serum PAPP-A and Urinary Protein-Creatinine Ratio as Predictive Markers of Pregnancy Induced Hypertension.
Early Pregnancy-Associated Plasma Protein A Concentrations are Associated with Third Trimester Insulin Sensitivity.
Efficacy of combined medication of nifedipine and magnesium sulfate on gestational hypertension and the effect on PAPP-A, VEGF, NO, Hcy and vWF.
Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks.
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension.
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
Improved prediction of gestational hypertension by inclusion of placental growth factor and pregnancy associated plasma protein-a in a sample of Ghanaian women.
Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Obstetrical complications associated with abnormal maternal serum markers analytes.
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Infant, Newborn, Diseases
PAPP-A and free ?-hCG in relation to admission to neonatal intensive care unit and neonatal disease.
Infections
Combined first-trimester Down syndrome screening in HIV-infected women.
First and Second Trimester Markers of Fetal Aneuploidy in Pregnant Women with HIV Infection.
Pregnancy-Associated Plasma Protein A as an Independent Mortality Predictor in Long-Term Hemodialysis Patients.
Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.
[Inflammation in atherosclerosis]
Infertility
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis.
First trimester screening for Down's syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10-14 weeks of gestation.
Increased pregnancy-associated plasma protein-A (PAPP-A) concentrations in peritoneal fluid of women with endometriosis.
Longer time-to-pregnancy in spontaneously conceived pregnancies is associated with lower PAPP-A and free ?-hCG in first trimester screening for Down syndrome.
Inflammatory Bowel Diseases
The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2 / PAPP-A / IGFBP-4 axis.
Insulin Resistance
Early Pregnancy-Associated Plasma Protein A Concentrations are Associated with Third Trimester Insulin Sensitivity.
Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age.
Metabolic consequences of pregnancy-associated plasma protein-A deficiency in mice: exploring possible relationship to the longevity phenotype.
Novel Modulators of the Growth Hormone - Insulin-Like Growth Factor Axis: Pregnancy-Associated Plasma Protein-A2 and Stanniocalcin-2.
PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against gestational diabetes in mice and humans.
Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.
Intervertebral Disc Degeneration
The relationship between pregnancy-associated plasma protein-A (PAPP-A) and human intervertebral disc degeneration.
Ischemic Attack, Transient
Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.
Ischemic Stroke
Association of pregnancy-associated plasma protein-A gene polymorphism with ischemic stroke in northern Chinese Han population.
Correlation of plasma soluble cluster of differentiation 40 ligand, alpha fetoprotein A, and pregnancy-associated plasma protein A with carotid plaque in patients with ischemic stroke.
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Genetic relationship between serum pregnancy-associated plasma protein-A gene polymorphism and ischemic cerebrovascular disease in a Northern Han Chinese population.
Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease.
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
The prognostic value of serum pregnancy-associated plasma protein A, S100 and high sensitivity C-reactive protein in acute ischemic stroke patients without heparin administration.
Kidney Diseases
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Kidney Failure, Chronic
Association of E-Selectin Gene Polymorphism and Serum PAPP-A with Carotid Atherosclerosis in End-Stage Renal Disease.
PAPP-A in cardiac and non-cardiac conditions.
Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.
Leiomyoma
Identification of genes with higher expression in human uterine leiomyomas than in the corresponding myometrium.
Lung Diseases
Insulin-Like Growth Factor Bioactivity, Stanniocalcin-2, Pregnancy-Associated Plasma Protein-A, and IGF-Binding Protein-4 in Pleural Fluid and Serum From Patients With Pulmonary Disease.
Lung Injury
Epithelial lining fluid free IGF-I-to-PAPP-A ratio is associated with bronchopulmonary dysplasia in preterm infants.
Lung Neoplasms
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
IGFBP-4: A promising biomarker for lung cancer.
PAPP-A and cancer.
Pregnancy-Associated Plasma Protein-A2 Is Associated With Mortality in Patients With Lung Cancer.
Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo.
Relationship between pregnancy-associated plasma protein-A and lung cancer.
Lymphangioma, Cystic
First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Rare chromosomal abnormalities: Can they be identified using conventional first trimester combined screening methods?
Malnutrition
Serum pregnancy-associated plasma protein A correlates with inflammation and malnutrition in patients treated with maintenance hemodialysis.
Mastocytosis
Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis.
Melanoma
Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Mesothelioma
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Mesothelioma, Malignant
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Metabolic Diseases
Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.
Metabolic Syndrome
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Microcephaly
Prenatal diagnosis and molecular cytogenetic characterization of de novo pure partial trisomy 6p associated with microcephaly, craniosynostosis and abnormal maternal serum biochemistry.
Migraine Disorders
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Migraine with Aura
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
MINOCA
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.
Multicystic Dysplastic Kidney
Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two-vessel cord, and hydrocele.
Multiple Sclerosis
The clinical course of multiple sclerosis during pregnancy and the puerperium.
Myocardial Infarction
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Biomarkers for early detection of risk in female patients with coronary artery disease: pilot study.
Circulating pregnancy-associated plasma protein A is not an early marker of acute myocardial infarction.
Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.
Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation.
Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients.
Diagnostic performance of high-sensitivity troponin T, myeloperoxidase, and pregnancy-associated plasma protein a assays for triage of patients with acute myocardial infarction.
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Examination of serum pregnancy-associated plasma protein A clinical value in acute coronary syndrome prediction and monitoring.
Free vs Total Pregnancy-Associated Plasma Protein A (PAPP-A) as a Predictor of 1-Year Outcome in Patients Presenting with Non-ST-Elevation Acute Coronary Syndrome.
Genetic polymorphism in the pregnancy-associated plasma protein-A associated with acute myocardial infarction.
Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach.
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy-associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction.
Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy.
Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI.
PAPP-A: a possible pathogenic link to the instability of atherosclerotic plaque.
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Pregnancy Associated Plasma Protein-A (PAPP-A) Levels in Acute Coronary Syndrome: A Case Control Study in a Tertiary Care Centre.
Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Pregnancy-associated plasma protein A (PAPP-A) for the early diagnosis of myocardial infarction: More doubts than certainties.
Pregnancy-associated plasma protein A and its endogenous inhibitor, the proform of eosinophil major basic protein (proMBP), are related to complex stenosis morphology in patients with stable angina pectoris.
Pregnancy-associated plasma protein A as a marker of acute coronary syndromes.
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Pregnancy-associated plasma protein A values in patients with stable cardiovascular disease: Use of a new monoclonal antibody-based assay.
Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI).
Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice?
Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases--a pilot study.
Pregnancy-associated plasma protein-a, a marker for outcome in patients suspected for acute coronary syndrome.
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina.
Relationship between Serum Levels of Pregnancy Associated Plasma Protein A and Coronary Artery Disease in Males.
Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes.
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
Temporal course of pregnancy-associated plasma protein-A in angioplasty-treated ST-elevation myocardial infarction patients and potential significance of concomitant heparin administration.
The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-elevation myocardial infarction: a brief communication.
The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction.
The long-term prognostic value of multiple biomarkers following a myocardial infarction.
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome.
[Measurement peripheral blood index related to inflammation and ox-LDL, ox-LDLAb in patients with coronary heart disease and its clinical significance]
Myocardial Ischemia
Markers for early detection of cardiac diseases.
Myocardial and Peripheral Ischemia Causes an Increase in Circulating Pregnancy-Associated Plasma Protein-A in Non-atherosclerotic, Non-heparinized Pigs.
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
Neoplasm Metastasis
Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.
Pregnancy-associated plasma protein a in cancer: expression, oncogenic functions and regulation.
Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Neoplasms
A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts.
A pilot study of the clinical relevance of the relationship between the serum level of pregnancy-associated plasma protein A and the degree of acute coronary syndrome.
Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes.
Annulus cells from more degenerated human discs show modified gene expression in 3D culture compared with expression in cells from healthier discs.
Association of endocannabinoids with pain in endometriosis.
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Bikunin target genes in ovarian cancer cells identified by microarray analysis.
Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NF?B Signaling in Hepatocellular Carcinoma.
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer.
Correlation between symptoms of pain and peritoneal fluid inflammatory cytokine concentrations in endometriosis.
CRP and TNF-???induce PAPP-A expression in human peripheral blood mononuclear cells.
Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol.
Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells.
Early pregnancy reference intervals; 29 serum analytes from 4 to 12 weeks' gestation in naturally conceived and uncomplicated pregnancies resulting in live births.
Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.
F2-isoprostanes in kidney transplant patients: relationship with inflammatory markers.
Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age.
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Identification and characterization of renal cell carcinoma gene markers.
Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells.
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
IGFBP-4 and PAPP-A in normal physiology and disease.
IGFBP-4: A promising biomarker for lung cancer.
Insulin-like growth factor, insulin-like growth factor-binding protein-4, and pregnancy-associated plasma protein-A gene expression in human granulosa cell tumors.
Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy
Is pregnancy-associated plasma protein A a tumor marker?
Lactation opposes pappalysin-1-driven pregnancy-associated breast cancer.
Longevity and Age-Related Pathology of Mice Deficient in Pregnancy-Associated Plasma Protein-A.
Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression.
Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: identification of a novel inducible inhibitor.
Motor and memory testing of long-lived pregnancy-associated plasma protein--a knock-out mice.
Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications.
Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation.
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo.
PAPP-A and cancer.
PAPP-A functions as a tumor suppressor and is downregulated in renal cell carcinoma.
PAPP-A in cardiac and non-cardiac conditions.
PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.
PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma.
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.
Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.
Placental proteins in male serum.
Posttransplant inflammation associated with onset of chronic kidney disease.
Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.
Preferential expression of PAPPA in human preadipocytes from omental fat.
Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion.
Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
Pregnancy-associated plasma protein a in cancer: expression, oncogenic functions and regulation.
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells.
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
Pregnancy-Associated Plasma Protein-A Accelerates Atherosclerosis by Regulating Reverse Cholesterol Transport and Inflammation.
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Pregnancy-associated plasma protein-A expression in human breast cancer.
Pregnancy-Associated Plasma Protein-A2 Is Associated With Mortality in Patients With Lung Cancer.
Pretransplant inflammation: a risk factor for delayed graft function?
Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events.
Production of pregnancy-associated plasma protein-A (PAPP-A) by cultured tumour granulosa cells.
Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial.
Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo.
Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
Regulation of pregnancy-associated plasma protein-A expression in cultured human osteoblasts.
Review: immunomodulatory activity of pregnancy-associated plasma protein-A.
Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus.
The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.
The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
Whole-genome reconstruction and mutational signatures in gastric cancer.
[Effects of C-reactive protein and tumor necrosis factor-alpha on mRNA expression of pregnancy-associated plasma protein-A in monocytes]
[Expression and activity of proteases in metastasis of ovarian cancer].
[Inflammation in atherosclerosis]
[Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIESTA Study (Systemic Inflammation Evaluation in Patients with non-ST segment elevation Acute coronary syndromes)]
[Pregnancy proteins]
[Relationship between the expression levels of PAPP-A metalloproteinase and growth and transcriptional factors in endometrial cancer].
Neoplasms, Germ Cell and Embryonal
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Neural Tube Defects
Diagnosis of fetal acrania during the first trimester nuchal translucency screening for Down syndrome.
Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
Non-ST Elevated Myocardial Infarction
A Plaque Disruption Index Identifies Patients with Non-STE-Type 1 Myocardial Infarction within 24 Hours of Troponin Positivity.
Obesity
Female PAPP-A knockout mice are resistant to metabolic dysfunction induced by high-fat/high-sucrose feeding at middle age.
Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation.
Preferential expression of PAPPA in human preadipocytes from omental fat.
Obesity, Abdominal
Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.
Preferential Impact of Pregnancy Associated Plasma Protein-A Deficiency on Visceral Fat in Mice on High Fat Diet.
Obstetric Labor, Premature
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Late pregnancy associated plasma protein A levels decrease in preterm labor.
Low maternal serum levels of pregnancy-associated plasma protein-A during the first trimester are associated with subsequent preterm delivery with preterm premature rupture of membranes.
PAPP-A levels as an early marker of idiopathic preterm birth: a pilot study.
Relationship Between Pregnancy Complications and Serum Pregnancy Associated-Plasma-Protein-A and Free-?-Human Chorionic Gonadotropin in the First Trimester Among Iranian Women.
The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.
Oligohydramnios
Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome.
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases?
Ultrasound and circulating placental protein measurements in complications of early pregnancy.
Oligospermia
Measurement of the pregnancy-associated proteins, placental protein 14 and pregnancy-associated plasma protein A in human seminal plasma.
Osteoporosis
Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.
Osteosarcoma
Covalent interaction between proform of eosinophil major basic protein (proMBP) and pregnancy-associated plasma protein-A (PAPP-A) is a cell-mediated event and required for proMBP inhibition of the catalytic activity of PAPP-A.
Pregnancy-associated plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by degrading IGFBP-4 in vitro.
Ovarian Diseases
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle.
Ovarian Neoplasms
A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts.
Characterization of the common fragile site FRA9E and its potential role in ovarian cancer.
Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis.
Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy
Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
Overexpression of pregnancy-associated plasma protein-a in ovarian cancer cells promotes tumor growth in vivo.
Pregnancy-associated plasma protein-A (PAPP-A) expression and insulin-like growth factor binding protein-4 protease activity in normal and malignant ovarian surface epithelial cells.
pappalysin-1 deficiency
Adult height and long-term outcomes after rhIGF-1 therapy in two patients with PAPP-A2 deficiency.
Comparative gene expression and phenotype analyses of skeletal muscle from aged wild-type and PAPP-A-deficient mice.
Disorders caused by genetic defects associated with GH-dependent genes: PAPPA2 defects.
Genetics of Growth Disorders-Which Patients Require Genetic Testing?
Inducible knock out of pregnancy-associated plasma protein-a gene expression in the adult mouse: effect on vascular injury response.
Inhibition of longevity regulator PAPP-A modulates tissue homeostasis via restraint of mesenchymal stromal cells.
Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation.
Metabolic consequences of pregnancy-associated plasma protein-A deficiency in mice: exploring possible relationship to the longevity phenotype.
Metabolomics changes in patients with PAPP-A2 deficiency in response to rhIGF1 treatment.
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.
Preferential Impact of Pregnancy Associated Plasma Protein-A Deficiency on Visceral Fat in Mice on High Fat Diet.
Pregnancy Associated Plasma Protein A2 (PAPP-A2) Affects Bone Size and Shape and Contributes to Natural Variation in Postnatal Growth in Mice.
Pregnancy-associated plasma protein-A deficiency improves survival of mice on a high fat diet.
Pregnancy-associated plasma protein-A2 (PAPP-A2): tissue expression and biological consequences of gene knockout in mice.
rhIGF-1 Treatment Increases Bone Mineral Density and Trabecular Bone Structure in Children with PAPP-A2 Deficiency.
Short stature with low insulin-like growth factor 1 availability due to pregnancy-associated plasma protein A2 deficiency in a Saudi family.
Suppression of PAPP-A mitigates atherosclerosis by mediating macrophage polarization via STAT3 signaling.
Treatment with recombinant human insulin-like growth factor-I improves growth in patients with PAPP-A2 deficiency.
Pediatric Obesity
Pregnancy-associated plasma protein A (PAPP-A) in obese children: relation to markers and risk factors of atherosclerosis, and members of the IGF system.
Pelvic Infection
Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.
Periapical Periodontitis
The importance of inflammatory biomarkers, IL-6 and PAPP-A, in the evaluation of asymptomatic apical periodontitis.
Pericardial Effusion
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women.
Perinatal Death
First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction.
Peripheral Arterial Disease
Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study.
Pregnancy-associated plasma protein-A as a marker for long-term mortality in patients with peripheral atherosclerosis: inconclusive findings from the Linz Peripheral Arterial Disease (LIPAD) study.
Peripheral Vascular Diseases
Elevated pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
Gender-Related Differences in Patients Presenting with Suspected Acute Coronary Syndromes: Clinical Presentation, Biomarkers and Diagnosis.
Placenta Accreta
Elevated first trimester PAPP-A is associated with increased risk of placenta accreta.
First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.
Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
[Prognostic significance of specific proteins of pregnancy in women with a uterine scar and placenta accreta.]
Placenta Previa
First trimester serum PAPP-A is associated with placenta accreta: a retrospective study.
Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
Placental Insufficiency
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome.
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
Pleural Effusion
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Pneumonia
Prognostic value of serum pregnancy-associated plasma protein A level at the initial ED presentation in elderly patients with CAP.
Polycystic Kidney Diseases
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
Polycystic Kidney, Autosomal Dominant
Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.
Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis.
Polycystic Ovary Syndrome
Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Serum and follicular fluid levels of IGF-II, IGF-binding protein-4 and pregnancy-associated plasma protein-A in controlled ovarian hyperstimulation cycle between polycystic ovarian syndrome (PCOS) and non-PCOS women.
Polyhydramnios
Identification of a prenatal profile of Cornelia de Lange syndrome (CdLS): A review of 53 CdLS pregnancies.
Pre-Eclampsia
?hCG and PAPP-A in First Trimester: Predictive Factors for Preeclampsia?
A prospective study of screening for hypertensive disorders of pregnancy at 11-13 weeks in a Scandinavian population.
A robust immunoassay for pregnancy-associated plasma protein-A2 based on analysis of circulating antigen: establishment of normal ranges in pregnancy.
ADAM 12 and PAPP-A at 14-17 weeks' gestation as biomarkers of pre-eclampsia.
ADAM12 and PAPP-A: Candidate regulators of trophoblast invasion and first trimester markers of healthy trophoblasts.
ADAM12s in maternal serum as a potential marker of pre-eclampsia.
Adverse pregnancy outcome in patients with low pregnancy-associated plasma protein-A: The Indian Experience.
Angiogenic and antiangiogenic factors in preeclampsia.
Application of metabolomics to preeclampsia diagnosis.
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Are Women with a History of Low PAPP-A at Risk for Adverse Perinatal Outcomes in a Subsequent Pregnancy?
Assessment of ?-human-derived chorionic gonadotrophic hormone (?hCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study.
Association between fetal fraction on cell-free DNA testing and first trimester markers for pre-eclampsia.
Association between first-trimester maternal serum pregnancy-associated plasma protein-A and obstetric complications.
Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.
Association of pregnancy-associated plasma protein A polymorphism with preeclampsia - a pilot study.
Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis.
Biochemical Markers for Prediction of Hypertensive Disorders of Pregnancy.
Biochemical markers in screening for preeclampsia and intrauterine growth restriction.
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Biomarkers in pre-eclampsia: A novel approach to early detection of the disease.
Can first trimester placental protein-13 and pregnancy-associated plasma protein-A predict pre-eclampsia in Turkish women?
CircRNA-0004904, CircRNA-0001855, and PAPP-A: Potential Novel Biomarkers for the Prediction of Preeclampsia.
Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Combination of PAPPA, fhCG?, AFP, PlGF, sTNFR1, and Maternal Characteristics in Prediction of Early-onset Preeclampsia.
Comparison of preeclampsia and fetal growth restriction screenings at first trimester in a high-risk population.
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
Competing-risks model for prediction of small-for-gestational-age neonates from maternal characteristics, serum PAPP-A and PlGF at 11-13?weeks' gestation.
Concentration of pregnancy-associated plasma protein A (PAPP-A) in patients with pre-eclamptic toxaemia.
Could first-trimester assessment of placental functions predict preeclampsia and intrauterine growth restriction? A prospective cohort study.
Could mean platelet volume in late first trimester of pregnancy predict intrauterine growth restriction and pre-eclampsia?
Cys327Cys polymorphism of the PAPP-A gene (pregnancy associated plasma protein A) is related to mortality of long term hemodialysis patients.
Decreased PAPP-A is associated with preeclampsia, premature delivery and small for gestational age infants but not with placental abruption.
Development and Validation of a Risk Factor Scoring System for First-Trimester Prediction of Preeclampsia.
Differential expression of human placental PAPP-A2 over gestation and in preeclampsia.
Does the Addition of Serum PAPP-A and ?-hCG Improve the Predictive Value of Uterine Artery Pulsatility Index for Preeclampsia at 11-14 Weeks of Gestation? A Prospective Observational Study.
Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity.
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study.
Early Prognostic Factors for the Progress of Preeclampsia - Our Experience in the Period 2010-2011.
Early-Onset Severe Preeclampsia by First Trimester Pregnancy-Associated Plasma Protein A and Total Human Chorionic Gonadotropin (Podcast).
Early-Onset Severe Preeclampsia by First Trimester Pregnancy-Associated Plasma Protein A and Total Human Chorionic Gonadotropin.
Effect of routine first trimester combined screening for pre-eclampsia on small for gestational age birth: a secondary interrupted time series analysis.
Efficiency of first-trimester uterine artery Doppler, a-disintegrin and metalloprotease 12, pregnancy-associated plasma protein a, and maternal characteristics in the prediction of preeclampsia.
Evaluation of fetal hypermethylated RASSF1A in pre-eclampsia and its relationship with placental protein-13, pregnancy associated plasma protein-A and urine protein.
Evaluation of maternal and perinatal outcomes among overweight women who experienced stillbirth.
Evaluation of serum ?-hCG and PAPP-A levels in pregnant women at risk of developing preeclampsia.
Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT.
Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks.
First trimester combined screening test for aneuploidies in anti-Ro carriers pregnant women.
First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction.
First trimester maternal serum PIGF, free ?-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia.
First trimester origins of fetal growth impairment.
First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia.
First trimester PAPP-A2, PAPP-A and hCG? in small-for-gestational-age pregnancies.
First trimester pregnancy-associated plasma protein A and human chorionic gonadotropin-beta in early and late pre-eclampsia.
First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia.
First trimester screening of late-onset preeclampsia in a low risk and low volume obstetrical setting.
First trimester serum PAPP-A and NGAL in the prediction of late-onset pre-eclampsia.
First trimester serum placental growth factor and hyperglycosylated human chorionic gonadotropin are associated with pre-eclampsia: a case control study.
First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy.
First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.
First-trimester 3-dimensional power Doppler placental vascularization indices from the whole placenta versus the placental bed to predict preeclampsia: does pregnancy-associated plasma protein a or uterine artery Doppler sonography help?
First-Trimester Inflammatory Markers for Risk Evaluation of Pregnancy Hypertension.
First-Trimester Levels of Pregnancy-Associated Plasma Protein A2 (PAPP-A2) in the Maternal Circulation Are Elevated in Pregnancies That Subsequently Develop Preeclampsia.
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.
First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia.
First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia.
First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia.
First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume.
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
First-Trimester Uterine Artery Pulsatility Index and Maternal Serum PAPP-A and PlGF in Prediction of Preeclampsia in Primigravida.
Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia.
Identifying mild and severe preeclampsia in asymptomatic pregnant women by levels of cell-free fetal DNA.
Impact of Endometriomas and Deep Infiltrating Endometriosis on Pregnancy Outcomes and on First and Second Trimester Markers of Impaired Placentation.
Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study.
Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients.
Low First Trimester Pregnancy-Associated Plasma Protein-A Levels Are Not Associated with an Increased Risk of Intrapartum Fetal Compromise or Adverse Neonatal Outcomes: A Retrospective Cohort Study.
Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes.
Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia.
Lower placental growth factor and higher free ?-hCG and PAPP-A levels in the fetal circulation of near-term pregnancies complicated with severe preeclampsia.
Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia.
Maternal hemodynamics in screen positive and negative women of the ASPRE trial.
Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy.
Maternal Serum Adiponectin at 11-13 Weeks of Gestation in Preeclampsia.
Maternal Serum Human Placental Growth Hormone (hPGH) at 11 to 13 Weeks of Gestation in Preeclampsia.
Maternal serum PAPP-A and free ß-hCG at 12, 22, 32 weeks' gestation in screening for pre-eclampsia.
Maternal serum placental growth factor and pregnancy-associated plasma protein A measured in the first trimester as parameters of subsequent pre-eclampsia and small-for-gestational-age infants: A prospective observational study.
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free ?-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Maternal Serum PLGF, PAPPA, ?-hCG and AFP Levels in Early Second Trimester as Predictors of Preeclampsia.
Maternal serum resistin at 11 to 13 weeks' gestation in normal and pathological pregnancies.
Maternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia.
New Predictive Model at 11+0 to 13+6 Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction.
Novel cardiovascular biomarkers in women with a history of early preeclampsia.
Obstetric Outcome in Pregnant Patients with Low Level of Pregnancy-Associated Plasma Protein A in First Trimester.
OS039. Early prediction of preeclampsia with maternal parameters,SVEGF-R1, PLGF, Inhibin-A and PAPP-A in general population: Results from the MSPE study.
OS087. Maternal characteristics, mean arterial pressure and PLGF in early prediction of preeclampsia.
PAPP-A levels of late pregnancy in preeclampsia and HELLP syndrome.
PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia.
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Performance of the FMF First-Trimester Preeclampsia-Screening Algorithm in a High-Risk Population in The Netherlands.
Placental protein-13 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for severe and early preeclampsia.
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Plasma mRNA concentrations of placenta-specific 1 (PLAC1) and pregnancy associated plasma protein A (PAPP-A) are higher in early-onset than late-onset pre-eclampsia.
PP13 and PAPP-A in the First and Second Trimesters: Predictive Factors for Preeclampsia?
Pre-eclampsia screening in the first trimester - preemptive action to prevent the peril.
Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free ?-hCG.
Prediction and prevention of pre-eclampsia in Asian subpopulation.
Prediction of adverse pregnancy outcomes by extreme values of first trimester screening markers.
Prediction of first-trimester preeclampsia: Relevance of the oxidative stress marker MDA in a combination model with PP-13, PAPP-A and beta-HCG.
Prediction of pre-eclampsia and its subtypes in high-risk cohort: hyperglycosylated human chorionic gonadotropin in multivariate models.
Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation.
Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13?weeks' gestation: data from EVENTS trial.
Prediction of Preeclampsia by First Trimester Combined Test and Simple Complete Blood Count Parameters.
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.
Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks.
Predictive value of combined serum biomarkers for adverse pregnancy outcomes.
Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37?weeks of pregnancy.
Pregnancy-associated and placental proteins in the placental tissue of normal pregnant women and patients with pre-eclampsia at term.
Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia.
Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects.
Pregnancy-associated plasma protein A gene polymorphism in pregnant women with preeclampsia and intrauterine growth restriction.
Pregnancy-associated plasma protein a polymorphisms in patients with risk pregnancies.
Pregnancy-associated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester.
Prospective evaluation of the first-trimester screening strategy for preterm pre-eclampsia and its clinical applicability in China.
Pulsatility index in combination with biomarkers or mean arterial pressure for the prediction of pre-eclampsia: Systematic literature review and meta-analysis.
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.
Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Screening for pre-eclampsia by maternal factors and biomarkers at 11-13?weeks' gestation.
Screening for preeclampsia in low-risk twin pregnancies at early gestation.
Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women.
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies.
Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia.
Serum Inhibin-A and PAPP-A2 in the prediction of pre-eclampsia during the first and second trimesters in high-risk women.
Serum Levels of Angiogenic Factors Distinguish Between Women with Preeclampsia and Normotensive Pregnant Women But Not Severity of Preeclampsia in an Obstetric Center in Turkey.
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Significance of pregnancy-associated plasma protein A (PAPP-A) concentration determination in the assessment of final outcome of pregnancy.
The potential role of pregnancy-associated plasma protein-A2 in angiogenesis and development of preeclampsia.
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.
The role of maternal serumbeta-HCG and PAPP-A levels at gestational weeks 10 to 14 in the prediction of pre-eclampsia.
The utility of first trimester uterine artery Doppler, placental volume and PAPP-A levels alone and in combination to predict preeclampsia.
The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia.
Use of first or second trimester serum markers, or both, to predict preeclampsia.
Use of FMF algorithm for prediction of preeclampsia in high risk pregnancies: a single center longitudinal study.
Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study.
Uteroplacental Ischemia Is Associated with Increased PAPP-A2.
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin.
[Low PAPP-A levels between 11 and 13(+6) weeks of gestation and the risk of preeclampsia].
Pregnancy Complications
Both Low and High PAPP-A Concentrations in the First Trimester of Pregnancy Are Associated with Increased Risk of Delivery before 32 Weeks in Twin Gestation.
First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications.
First trimester maternal serum PAPP-A levels and associated pregnancy complications in intrahepatic cholestasis of pregnancy.
First trimester pregnancy-associated plasma protein-A in pregnancies complicated by subsequent gestational diabetes.
Increased time-to-pregnancy and first trimester Down's syndrome screening.
PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia.
PAPP-A2 deficiency does not exacerbate the phenotype of a mouse model of intrauterine growth restriction.
Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A.
Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler.
Serum pregnancy-associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
The influence of parity and gravidity on first trimester markers of chromosomal abnormality.
[Prediction of adverse pregnancy outcome by first-trimester maternal serum PAPP-A]
Pregnancy, Ectopic
Accuracy of single measurements of pregnancy-associated plasma protein-A, human chorionic gonadotropin and progesterone in the diagnosis of early pregnancy failure.
Are pregnancy-associated plasma protein-A (PAPP-A) and CA 125 measurements after IVF-ET possible predictors of early pregnancy wastage?
Circulating and tissue concentrations of pregnancy-associated plasma protein-A (PAPP-A) in tubal ectopic gestation.
Circulating levels of pregnancy-associated plasma protein-A (PAPP-A) and human chorionic gonadotrophin (hCG) in intrauterine and extrauterine pregnancies.
Corpus luteum failure in ectopic pregnancy.
Predicting first trimester pregnancy outcome: derivation of a multiple marker test.
Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.
Pregnancy-associated plasma protein A in pregnancy-related gynaecologic emergency.
The disappearance rate of pregnancy-associated plasma protein-A (PAPP-A) after the end of normal and abnormal pregnancies.
The value of vascular endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous miscarriages.
Pregnancy, High-Risk
Is pregnancy associated plasma protein-A (PAPP-A) a marker for adverse perinatal outcomes in preterm isolated oligohydramnios cases?
Placental volume and vascularization flow indices by 3D power Doppler US using VOCAL technique and correlation with IGF-1, free beta-hCG, PAPP-A, and uterine artery Doppler at 11-14 weeks of pregnancy.
Pregnancy, Tubal
Circulating and tissue concentrations of pregnancy-associated plasma protein-A (PAPP-A) in tubal ectopic gestation.
The prediction of pregnancy failure by measurement of pregnancy-associated plasma protein A (PAPP-A) following in vitro fertilization and embryo transfer.
Premature Birth
Adverse pregnancy outcome in patients with low pregnancy-associated plasma protein-A: The Indian Experience.
Are the first-trimester levels of PAPP-A and fb-hCG predictors for obstetrical complications in diabetic pregnancy?
Association of first-trimester low PAPP-A levels with preterm birth.
Association of first-trimester pregnancy-associated plasma protein A levels and idiopathic preterm delivery: A population-based screening study.
Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis.
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Confined placental mosaicism revisited: Impact on pregnancy characteristics and outcome.
Correlation of first-trimester serum levels of pregnancy-associated plasma protein A with small-for-gestational-age neonates and preterm births.
Decreased First-trimester Maternal Serum Free-beta Subunit Human Chorionic Gonadotropin and Preterm Birth in Twin Gestations.
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
First trimester pregnancy associated plasma protein-A as a marker for poor pregnancy outcome in patients with early-onset fetal growth restriction.
First-trimester maternal serum biomarkers and the risk of cerebral palsy.
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
First-trimester prediction of preterm birth using ADAM12, PAPP-A, uterine artery Doppler, and maternal characteristics.
First-trimester serum biomarker screening for fetal Down syndrome as a predictor of preterm delivery: a population-based study.
First-trimester serum PAPP-A and f?-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Late pregnancy associated plasma protein A levels decrease in preterm labor.
Low First Trimester Pregnancy-Associated Plasma Protein-A Levels Are Not Associated with an Increased Risk of Intrapartum Fetal Compromise or Adverse Neonatal Outcomes: A Retrospective Cohort Study.
PAPP-A levels as an early marker of idiopathic preterm birth: a pilot study.
Prediction of preterm birth in nulliparous women using logistic regression and machine learning.
Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.
The predictive value of 18 and 22 week uterine artery Doppler in patients with low first trimester maternal serum PAPP-A.
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
The Relationship of Pregnancy-Associated Plasma Protein A and Human Chorionic Gonadotropin with Adverse Pregnancy Outcomes: A Prospective Study.
Use of prokineticin-1 (PROK1), pregnancy-associated plasma protein A (PAPP-A) and PROK1/PAPP-A ratio to predict adverse pregnancy outcomes in the first trimester: a prospective study.
Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes.
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Proteinuria
First trimester PAPP-A2, PAPP-A and hCG? in small-for-gestational-age pregnancies.
Obstetrical complications associated with abnormal maternal serum markers analytes.
PAPP-A2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia.
Pregnancy-associated plasma protein A: spotlight on kidney diseases.
Pregnancy-associated plasma protein-A: evaluation of a new biomarker in renal transplant patients.
Psoriasis
Can pregnancy-associated plasma protein-A be a marker for the assessment of atherosclerosis risk in patients with chronic plaque psoriasis?
Evaluation of pregnancy-associated plasma protein-A and some inflammation markers for atherosclerosis in psoriasis patients.
Puberty, Precocious
Genomic association for sexual precocity in beef heifers using pre-selection of genes and haplotype reconstruction.
Pulmonary Disease, Chronic Obstructive
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Pregnancy-associated plasma protein-A (PAPP-A) and the proform of the eosinophil major basic protein (ProMBP) are associated with increased risk of death in heart failure patients.
THE ROLE OF LIPOPROTEIN (A) AND PREGNANCY ASSOCIATED PLASMA PROTEIN A IN DIAGNOSTICS CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
Pulmonary Embolism
Diagnostic usefulness of pregnancy-associated plasma protein-A in suspected pulmonary embolism.
Evaluation of Pregnancy-Associated Plasma Protein-A Levels in Patients with Chronic Obstructive Pulmonary Disease and Associations with Disease Severity.
Pyelectasis
Genetic sonography after first-trimester Down syndrome screening.
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women.
Renal Insufficiency
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Renal Insufficiency, Chronic
Determinants of circulating matrix metalloproteinase-2 and pregnancy-associated plasma protein-A in patients with chronic kidney disease.
Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: a cross sectional study.
Pregnancy-associated plasma protein A (PAPP-A) and soluble receptor for advanced glycation end products (sRAGE) - intra- and inter-individual variability in chronic hemodialysis patients.
Pregnancy-associated plasma protein A as a predictor of all-cause mortality and cardiovascular events in patients with chronic kidney disease: a meta-analysis of prospective studies.
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
Respiratory Distress Syndrome
Can first trimester pregnancy-associated plasma protein-A predict the surfactant needs of preterm neonates?
The utility of pregnancy associated plasma protein-A MoM values in prediction of term respiratory distress syndrome.
Retinal Vein Occlusion
Increased pregnancy-associated plasma protein A in retinal vein occlusion.
Rhinitis, Allergic
Does pregnancy-associated plasma protein A have a role in allergic rhinitis?
Sarcoma, Ewing
EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1.
PAPP-A and cancer.
Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.
The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning.
Seminoma
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Sepsis
Elevated pregnancy-associated plasma protein A predicts myocardial dysfunction and death in severe sepsis.
Severe Combined Immunodeficiency
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
Single Umbilical Artery
Comparison of fetal weight distribution improved by paternal height by Spanish standard versus Intergrowth 21st standard.
The effects of isolated single umbilical artery on first and second trimester aneuploidy screening test parameters.
Sleep Apnea, Obstructive
The Relation between Pregnancy-Associated Plasma Protein A and Obstructive Sleep Apnea Syndrome.
Spondylitis, Ankylosing
Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors.
ST Elevation Myocardial Infarction
Levels of pregnancy-associated plasma protein A in patients with coronary artery disease.
Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction.
Pregnancy-associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI).
Relationship between Serum Levels of Pregnancy Associated Plasma Protein A and Coronary Artery Disease in Males.
Release patterns of pregnancy-associated plasma protein A in patients with acute coronary syndromes assessed by an optimized monoclonal antibody assay.
The activity of pregnancy-associated plasma protein A (PAPP-A) as expressed by immunohistochemistry in atherothrombotic plaques obtained by aspiration thrombectomy in patients presenting with a ST-elevation myocardial infarction: a brief communication.
The Role of Insulin-Like Growth Factor-1 and Pregnancy-Associated Plasma Protein-A in Diagnosis of Acute Coronary Syndrome and Its Related Morbidities.
Usefulness of pregnancy-associated plasma protein A in patients with acute coronary syndrome.
Stillbirth
Adverse Fetal outcome: Is first trimester ultrasound and Doppler better predictor than biomarkers?
Association between first trimester maternal serum pregnancy associated plasma protein-A and adverse pregnancy outcome.
Association of maternal serum PAPP-A levels, nuchal translucency and crown-rump length in first trimester with adverse pregnancy outcomes: retrospective cohort study.
Biology of pregnancy-associated plasma protein-A in relation to prenatal diagnostics: an overview.
Clinical Importance of Low Level of PAPP-A in First Trimester of Pregnancy - An Obstetrical Dilemma in Chromosomally Normal Fetus.
Does first-trimester serum pregnancy-associated plasma protein A differ in pregnant women with sickle cell disease?
Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth.
First trimester origins of fetal growth impairment.
First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.
First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
First-trimester placentation and the risk of antepartum stillbirth.
First-trimester serum PAPP-A and f?-hCG concentrations and other maternal characteristics to establish logistic regression-based predictive rules for adverse pregnancy outcome.
Low maternal PAPP-A is associated with small-for-gestational age newborns and stillbirths.
Low maternal pregnancy-associated plasma protein A during the first trimester of pregnancy and pregnancy outcomes.
Placental growth factor in prediction of stillbirths at 11-13 weeks.
Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A.
Prediction and prevention of recurrent stillbirth.
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Prediction of stillbirth from placental growth factor at 11-13 weeks.
Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome.
Record linkage to obtain birth outcomes for the evaluation of screening biomarkers in pregnancy: a feasibility study.
The Reactivity Levels of Progesterone, Nitric Oxide and Nuclear Factor Kappa-B on the Serum of Term and Post-Term Pregnancy, Clinical Study in Padang, West Sumatera, Indonesia.
Variation of papp-a level in the first trimester of pregnancy and its clinical outcome.
Stomach Neoplasms
Whole-genome reconstruction and mutational signatures in gastric cancer.
Stroke
Association of cardiovascular emerging risk factors with acute coronary syndrome and stroke: A case-control study.
Maternal hemodynamic assessment by USCOM® device in the first trimester of pregnancy.
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
The prognostic value of serum pregnancy-associated plasma protein A, S100 and high sensitivity C-reactive protein in acute ischemic stroke patients without heparin administration.
[THE CLINICAL LABORATORY MARKERS OF ATHEROSCLEROSIS IN PATIENTS WITH ATHEROTHROMBOTIC STROKE].
Tension-Type Headache
Perinatal outcomes in women affected by different types of headache disorders: A prospective cohort study.
Teratoma
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Testicular Neoplasms
Pregnancy-associated plasma protein-A concentrations in men with testicular and prostatic tumors.
Tetralogy of Fallot
First trimester combined screening biochemistry in detection of congenital heart defects.
Thrombophilia
Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation.
The impact of inherited thrombophilia on first trimester combined aneuploidy screening test parameters.
Thrombosis
Elevated PAPP-A sets alarm bells ringing in patients with cardiac chest pain.
Evaluation of Serum Pregnancy Associated Plasma Protein-A & Plasma D-Dimer in Acute Coronary Syndrome.
Thyroid Neoplasms
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Thyroid Nodule
Pregnancy-associated plasma protein A mRNA expression as a marker for differentiated thyroid cancer: results from a "surgical" and a "cytological" series.
Toxemia
Placental and circulating pregnancy-associated plasma protein A concentrates in normal and pathological term pregnancies.
[Fluctuations in pregnancy-associated protein A (PAPP-A) levels in the sera of pregnant women]
Tricuspid Valve Insufficiency
First Trimester Screening for Chromosomal Abnormalities by Integrated Application of Nuchal Translucency, Nasal Bone, Tricuspid Regurgitation, Ductus Venosus Flow Combined with Maternal Serum Free ?-HCG and PAPP-A: A 5-Year Prospective Study.
First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.
Prenatal Aneuploidies Computerized Screening (SCA TEST): a pilot study on 1000 women.
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV.
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Trisomy 13 Syndrome
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
Aneuploidy screening in the first trimester.
First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.
First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free ?-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.
First trimester PAPP-A in the detection of non-Down syndrome aneuploidy.
Maternal serum placental protein 13 at eleven to thirteen weeks in chromosomally abnormal pregnancies.
Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
Maternal serum screening marker levels in women with a previous aneuploidy pregnancy.
Prenatal sonographic features of fetuses in trisomy 13 pregnancies. IV.
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Trisomy 18 Syndrome
A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.
ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy.
Aneuploidy screening in the first trimester.
Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency.
First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18.
First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies.
First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Gene expression of human pregnancy-associated plasma protein-A in placenta from trisomic pregnancies.
Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women.
Is ultrasound alone enough for prenatal screening of trisomy 18? A single centre experience in 69 cases over 10 years.
Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks.
Maternal serum human placental growth hormone at 11 to 13 weeks in trisomy 21 and trisomy 18 pregnancies.
Maternal serum pregnancy-associated plasma protein A (PAPP-A) but not pregnancy-specific beta1-glycoprotein (SP1) is a useful second-trimester marker for fetal trisomy 18.
Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
Maternal serum screening for trisomy 18 in the first trimester of pregnancy.
Pregnancy-associated plasma protein-A truncation limits in antenatal screening for trisomy 18.
Prenatal diagnosis of 5p deletion syndrome: Report of five cases.
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18.
Second trimester two-step trisomy 18 screening using maternal serum markers.
Second-trimester levels of pregnancy-associated plasma protein-A and free beta-hCG in pregnancies with trisomy 13.
Serum marker truncation limits in first trimester antenatal screening for trisomy 18.
The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (?-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Ultrasound and fetal diagnosis.
[First-Trimester Screening for Trisomies 18 and 13 with the Combined Use of the Risk Algorithms for Trisomy 21, 18 and 13.]
Trophoblastic Neoplasms
Is pregnancy-associated plasma protein A a tumor marker?
Turner Syndrome
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first trimester.
The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation.
Uterine Hemorrhage
Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
Comparison of serum and urine hCG levels with SP1 and PAPP-A levels in patients with first-trimester vaginal bleeding.
Does vaginal bleeding influence first-trimester markers for Down syndrome?
Early vaginal bleeding and first-trimester markers for Down syndrome.
Pregnancy-associated plasma protein A in the prediction of early pregnancy failure.
Ultrasound and circulating placental protein measurements in complications of early pregnancy.
Value of Schwangerschaftsprotein 1 (SP1) and pregnancy-associated plasma protein-A (PAPP-A) in the clinical management of threatened abortion.
Vascular Diseases
Elevated serum levels of pregnancy-associated plasma protein-A in type 2 diabetics compared to healthy controls: associations with subclinical atherosclerosis parameters.
Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
Vascular System Injuries
Constitutive expression of pregnancy-associated plasma protein-A in arterial smooth muscle reduces the vascular response to injury in vivo.
Cytokine stimulation of pregnancy-associated plasma protein A expression in human coronary artery smooth muscle cells: inhibition by resveratrol.
Inducible knock out of pregnancy-associated plasma protein-a gene expression in the adult mouse: effect on vascular injury response.
Pregnancy-associated plasma protein A: Has this biomarker crossed the boundary from research to clinical practice?
Targeted disruption of the pregnancy-associated plasma protein-A gene is associated with diminished smooth muscle cell response to insulin-like growth factor-I and resistance to neointimal hyperplasia after vascular injury.
Venous Thrombosis
Increased pregnancy-associated plasma protein A in retinal vein occlusion.
Vitamin D Deficiency
Association between maternal circulating 25 hydroxyvitamin D concentration and placental volume in the first trimester.